Compendium of Cancer Genome Aberrations

HAEM5:Volunteer Assignments and Opportunities: Difference between revisions

[unchecked revision][unchecked revision]
← Older editNewer edit →
VisualWikitext
No edit summary
No edit summary
Line 5: Line 5:
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Correlated Prior Author (4th Edition)
!Content Status (4th Edition)(Pending or Complete)
!Date of Last Editor Review (4th Edition)
!Date of Last Editor Review (4th Edition)
!Notes (4th Edition)
!Notes (4th Edition)
Line 13: Line 14:
|
|
----<br />
----<br />
|
|
|
|
|
Line 26: Line 28:
|-
|-
|Clonal haematopoiesis||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)|| ||
|Clonal haematopoiesis||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)|| ||
|NEW DISEASE
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|
|
|-
|-
|Clonal cytopenias of undetermined significance||Disease|| || || || || ||FQR|| ||
|Clonal cytopenias of undetermined significance||Disease|| || || || || ||FQR|| ||
|NEW DISEASE
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|
|
|-
|-
|Chronic myeloid leukaemia||Disease|| || || || || ||FQR|| ||
|Chronic myeloid leukaemia||Disease|| || || || || ||FQR|| ||
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive
|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
|
|Date page was created
|Date page was created
|
|
Line 46: Line 51:
|Chronic Neutrophilic Leukemia (CNL)
|Chronic Neutrophilic Leukemia (CNL)
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally
|
|Date page was created
|Date page was created
|
|
Line 52: Line 58:
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
|Chelsea D. Kramish; Daynna J.Wolff
|Chelsea D. Kramish; Daynna J.Wolff
|
|
|
|
|
Line 58: Line 65:
|Polycythemia Vera (PV)
|Polycythemia Vera (PV)
|Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center
|Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center
|
|
|
|
|
|-
|-
|Essential thrombocythaemia||Disease||Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN|| || || || ||FQR|| ||
|Essential thrombocythaemia||Disease|| || || || || ||FQR|| ||
|Essential Thrombocythemia (ET)
|Essential Thrombocythemia (ET)
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN
|
|
|
|
Line 68: Line 77:
|-
|-
|Primary myelofibrosis||Disease||T. Niroshi Senaratne, UCLA|| || || || ||FQR|| ||
|Primary myelofibrosis||Disease||T. Niroshi Senaratne, UCLA|| || || || ||FQR|| ||
|
|
|
|
|
Line 74: Line 84:
|-
|-
|Juvenile myelomonocytic leukaemia||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |Assistant Professor, Pathology  Associate Director | Division of Molecular Pathology, Genetics and Genomics  Duke University Health System Clinical Laboratories|| || || || ||FQR|| ||
|Juvenile myelomonocytic leukaemia||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |Assistant Professor, Pathology  Associate Director | Division of Molecular Pathology, Genetics and Genomics  Duke University Health System Clinical Laboratories|| || || || ||FQR|| ||
|
|
|
|
|
Line 80: Line 91:
|-
|-
|Myeloproliferative neoplasm, NOS||Disease||Thomas Lee, MD, PhD, University of California, Los Angeles|| || || || ||FQR|| ||
|Myeloproliferative neoplasm, NOS||Disease||Thomas Lee, MD, PhD, University of California, Los Angeles|| || || || ||FQR|| ||
|
|
|
|
|
Line 86: Line 98:
|-
|-
|Cutaneous mastocytosis||Disease||S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD|| || || || ||FQR|| ||
|Cutaneous mastocytosis||Disease||S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD|| || || || ||FQR|| ||
|
|
|
|
|
Line 92: Line 105:
|-
|-
|Systemic mastocytosis||Disease||'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University  '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University|| || || || ||FQR|| ||
|Systemic mastocytosis||Disease||'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University  '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University|| || || || ||FQR|| ||
|
|
|
|
|
Line 98: Line 112:
|-
|-
|Mast cell sarcoma||Disease||Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL|| || || || ||FQR|| ||
|Mast cell sarcoma||Disease||Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL|| || || || ||FQR|| ||
|
|
|
|
|
Line 104: Line 119:
|-
|-
|Myelodysplastic neoplasm with low blasts and 5q deletion||Disease|| || || || || ||FQR|| ||
|Myelodysplastic neoplasm with low blasts and 5q deletion||Disease|| || || || || ||FQR|| ||
|
|
|
|
|
Line 110: Line 126:
|-
|-
|Myelodysplastic neoplasm with low blasts and SF3B1 mutation||Disease|| || || || || ||FQR|| ||
|Myelodysplastic neoplasm with low blasts and SF3B1 mutation||Disease|| || || || || ||FQR|| ||
|
|
|
|
|
Line 116: Line 133:
|-
|-
|Myelodysplastic neoplasm with biallelic TP53 inactivation||Disease|| || || || || ||FQR|| ||
|Myelodysplastic neoplasm with biallelic TP53 inactivation||Disease|| || || || || ||FQR|| ||
|
|
|
|
|
Line 122: Line 140:
|-
|-
|Myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR|| ||
|Myelodysplastic neoplasm with low blasts||Disease|| || || || || ||FQR|| ||
|
|
|
|
|
Line 128: Line 147:
|-
|-
|Myelodysplastic neoplasm, hypoplastic||Disease|| || || || || ||FQR|| ||
|Myelodysplastic neoplasm, hypoplastic||Disease|| || || || || ||FQR|| ||
|
|
|
|
|
Line 134: Line 154:
|-
|-
|Myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
|Myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
|
|
|
|
|
Line 140: Line 161:
|-
|-
|Childhood myelodysplastic neoplasm with low blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
|Childhood myelodysplastic neoplasm with low blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
|
|
|
|
|
Line 146: Line 168:
|-
|-
|Childhood myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
|Childhood myelodysplastic neoplasm with increased blasts||Disease||Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.|| || || || ||FQR|| ||
|
|
|
|
|
Line 152: Line 175:
|-
|-
|Chronic myelomonocytic leukaemia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| ||
|Chronic myelomonocytic leukaemia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| ||
|
|
|
|
|
Line 158: Line 182:
|-
|-
|Myelodysplastic/myeloproliferative neoplasm with neutrophilia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| ||
|Myelodysplastic/myeloproliferative neoplasm with neutrophilia||Disease||Linsheng Zhang, MD, PhD|| || || || ||FQR|| ||
|
|
|
|
|
Line 164: Line 189:
|-
|-
|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis||Disease||Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine|| || || || ||FQR|| ||
|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis||Disease||Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine|| || || || ||FQR|| ||
|
|
|
|
|
Line 170: Line 196:
|-
|-
|Myelodysplastic/myeloproliferative neoplasm, NOS||Disease||Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia|| || || || ||FQR|| ||
|Myelodysplastic/myeloproliferative neoplasm, NOS||Disease||Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia|| || || || ||FQR|| ||
|
|
|
|
|
Line 176: Line 203:
|-
|-
|Myeloid/lymphoid neoplasm with PDGFRA rearrangement||Disease||Jay Alden, DO|| || || || ||FQR|| ||
|Myeloid/lymphoid neoplasm with PDGFRA rearrangement||Disease||Jay Alden, DO|| || || || ||FQR|| ||
|
|
|
|
|
Line 182: Line 210:
|-
|-
|Myeloid/lymphoid neoplasm with PDGFRB rearrangement||Disease||Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD|| || || || ||FQR|| ||
|Myeloid/lymphoid neoplasm with PDGFRB rearrangement||Disease||Christopher Sullivan, MD, MPH and Daynna J. Wolff, PhD|| || || || ||FQR|| ||
|
|
|
|
|
Line 188: Line 217:
|-
|-
|Myeloid/lymphoid neoplasm with FGFR1 rearrangement||Disease||Yanna Ding, MD PhD|| || || || ||FQR|| ||
|Myeloid/lymphoid neoplasm with FGFR1 rearrangement||Disease||Yanna Ding, MD PhD|| || || || ||FQR|| ||
|
|
|
|
|
Line 194: Line 224:
|-
|-
|Myeloid/lymphoid neoplasm with JAK2 rearrangement||Disease||Jessica Snider, M.D. and Daynna J. Wolff, PhD|| || || || ||FQR|| ||
|Myeloid/lymphoid neoplasm with JAK2 rearrangement||Disease||Jessica Snider, M.D. and Daynna J. Wolff, PhD|| || || || ||FQR|| ||
|
|
|
|
|
Line 200: Line 231:
|-
|-
|Myeloid/lymphoid neoplasm with FLT3 rearrangement||Disease|| || || || || ||FQR|| ||
|Myeloid/lymphoid neoplasm with FLT3 rearrangement||Disease|| || || || || ||FQR|| ||
|
|
|
|
|
Line 206: Line 238:
|-
|-
|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion||Disease|| || || || || ||FQR|| ||
|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion||Disease|| || || || || ||FQR|| ||
|
|
|
|
|
Line 212: Line 245:
|-
|-
|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes||Disease|| || || || || ||FQR|| ||
|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes||Disease|| || || || || ||FQR|| ||
|
|
|
|
|
Line 225: Line 259:
|
|
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
|
|
|
|
|
Line 240: Line 275:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 255: Line 291:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 270: Line 307:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 285: Line 323:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 300: Line 339:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 315: Line 355:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 330: Line 371:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 345: Line 387:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 360: Line 403:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 375: Line 419:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 390: Line 435:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 405: Line 451:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 420: Line 467:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 435: Line 483:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 450: Line 499:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 465: Line 515:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 480: Line 531:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 495: Line 547:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 510: Line 563:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 525: Line 579:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 540: Line 595:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 555: Line 611:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 570: Line 627:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 585: Line 643:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 600: Line 659:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 615: Line 675:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 630: Line 691:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 645: Line 707:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 660: Line 723:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 675: Line 739:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 690: Line 755:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 705: Line 771:
|
|
|JH_MS
|JH_MS
|
|
|
|
|
Line 717: Line 784:
|
|
----<br />
----<br />
|
|
|
|
|
Line 737: Line 805:
|
|
|Greg Corboy (GC)
|Greg Corboy (GC)
|
|
|
|
|
Line 752: Line 821:
|
|
|GC
|GC
|
|
|
|
|
Line 767: Line 837:
|
|
|GC
|GC
|
|
|
|
|
Line 782: Line 853:
|
|
|GC
|GC
|
|
|
|
|
Line 797: Line 869:
|
|
|GC
|GC
|
|
|
|
|
Line 812: Line 885:
|
|
|GC
|GC
|
|
|
|
|
Line 827: Line 901:
|
|
|GC
|GC
|
|
|
|
|
Line 842: Line 917:
|
|
|GC
|GC
|
|
|
|
|
Line 857: Line 933:
|
|
|GC
|GC
|
|
|
|
|
Line 872: Line 949:
|
|
|GC
|GC
|
|
|
|
|
Line 887: Line 965:
|
|
|GC
|GC
|
|
|
|
|
Line 899: Line 978:
|
|
----<br />
----<br />
|
|
|
|
|
Line 919: Line 999:
|
|
|GC
|GC
|
|
|
|
|
Line 934: Line 1,015:
|
|
|GC
|GC
|
|
|
|
|
Line 949: Line 1,031:
|
|
|GC
|GC
|
|
|
|
|
Line 964: Line 1,047:
|
|
|GC
|GC
|
|
|
|
|
Line 979: Line 1,063:
|
|
|GC
|GC
|
|
|
|
|
Line 994: Line 1,079:
|
|
|Holli Drendel (HD)
|Holli Drendel (HD)
|
|
|
|
|
Line 1,009: Line 1,095:
|
|
|HD
|HD
|
|
|
|
|
Line 1,024: Line 1,111:
|
|
|HD
|HD
|
|
|
|
|
Line 1,039: Line 1,127:
|
|
|HD
|HD
|
|
|
|
|
Line 1,054: Line 1,143:
|
|
|HD
|HD
|
|
|
|
|
Line 1,069: Line 1,159:
|
|
|HD
|HD
|
|
|
|
|
Line 1,084: Line 1,175:
|
|
|HD
|HD
|
|
|
|
|
Line 1,099: Line 1,191:
|
|
|HD
|HD
|
|
|
|
|
Line 1,114: Line 1,207:
|
|
|HD
|HD
|
|
|
|
|
Line 1,129: Line 1,223:
|
|
|HD
|HD
|
|
|
|
|
Line 1,144: Line 1,239:
|
|
|HD
|HD
|
|
|
|
|
Line 1,159: Line 1,255:
|
|
|HD
|HD
|
|
|
|
|
Line 1,174: Line 1,271:
|
|
|HD
|HD
|
|
|
|
|
Line 1,189: Line 1,287:
|
|
|HD
|HD
|
|
|
|
|
Line 1,198: Line 1,297:
|Monoclonal B-cell lymphocytosis||Disease|| || || || || ||Shivani Golem (SG)
|Monoclonal B-cell lymphocytosis||Disease|| || || || || ||Shivani Golem (SG)
| ||
| ||
|
|
|
|
|
Line 1,204: Line 1,304:
|-
|-
|Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease||Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD|| || || || ||SG|| ||
|Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease||Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD|| || || || ||SG|| ||
|
|
|
|
|
Line 1,210: Line 1,311:
|-
|-
|Hairy cell leukaemia||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
|Hairy cell leukaemia||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
|
|
|
|
|
Line 1,216: Line 1,318:
|-
|-
|Splenic marginal zone lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
|Splenic marginal zone lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
|
|
|
|
|
Line 1,222: Line 1,325:
|-
|-
|Splenic diffuse red pulp small B-cell lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
|Splenic diffuse red pulp small B-cell lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
|
|
|
|
|
Line 1,235: Line 1,339:
|
|
|SG
|SG
|
|
|
|
|
Line 1,250: Line 1,355:
|
|
|SG
|SG
|
|
|
|
|
Line 1,265: Line 1,371:
|
|
|SG
|SG
|
|
|
|
|
Line 1,280: Line 1,387:
|
|
|SG
|SG
|
|
|
|
|
Line 1,295: Line 1,403:
|
|
|SG
|SG
|
|
|
|
|
Line 1,310: Line 1,419:
|
|
|SG
|SG
|
|
|
|
|
Line 1,325: Line 1,435:
|
|
|SG
|SG
|
|
|
|
|
Line 1,340: Line 1,451:
|
|
|SG
|SG
|
|
|
|
|
Line 1,355: Line 1,467:
|
|
|SG
|SG
|
|
|
|
|
Line 1,370: Line 1,483:
|
|
|SG
|SG
|
|
|
|
|
Line 1,385: Line 1,499:
|
|
|SG
|SG
|
|
|
|
|
Line 1,400: Line 1,515:
|
|
|SG
|SG
|
|
|
|
|
Line 1,415: Line 1,531:
|
|
|SG
|SG
|
|
|
|
|
Line 1,430: Line 1,547:
|
|
|SG
|SG
|
|
|
|
|
Line 1,445: Line 1,563:
|
|
|SG
|SG
|
|
|
|
|
Line 1,453: Line 1,572:
|-
|-
|Diffuse large B-cell lymphoma, NOS||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
|Diffuse large B-cell lymphoma, NOS||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
|
|
|
|
|
Line 1,459: Line 1,579:
|-
|-
|T-cell/histiocyte-rich large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|T-cell/histiocyte-rich large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|
|
|
|
|
Line 1,465: Line 1,586:
|-
|-
|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
|
|
|
|
|
Line 1,471: Line 1,593:
|-
|-
|ALK-positive large B-cell lymphoma||Disease||Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)|| || || || ||GC|| ||
|ALK-positive large B-cell lymphoma||Disease||Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)|| || || || ||GC|| ||
|
|
|
|
|
Line 1,477: Line 1,600:
|-
|-
|Large B-cell lymphoma with IRF4 rearrangement||Disease||*Afia Hasnain, MBBS, PhD|| || || || ||GC|| ||
|Large B-cell lymphoma with IRF4 rearrangement||Disease||*Afia Hasnain, MBBS, PhD|| || || || ||GC|| ||
|
|
|
|
|
Line 1,483: Line 1,607:
|-
|-
|High grade B-cell lymphoma with 11q aberrations||Disease||Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina|| || || || ||GC|| ||
|High grade B-cell lymphoma with 11q aberrations||Disease||Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina|| || || || ||GC|| ||
|
|
|
|
|
Line 1,489: Line 1,614:
|-
|-
|Lymphomatoid granulomatosis||Disease|| || || || || ||GC|| ||
|Lymphomatoid granulomatosis||Disease|| || || || || ||GC|| ||
|
|
|
|
|
Line 1,495: Line 1,621:
|-
|-
|EBV-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|EBV-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|
|
|
|
|
Line 1,501: Line 1,628:
|-
|-
|Diffuse large B-cell lymphoma associated with chronic inflammation||Disease|| || || || || ||GC|| ||
|Diffuse large B-cell lymphoma associated with chronic inflammation||Disease|| || || || || ||GC|| ||
|
|
|
|
|
Line 1,507: Line 1,635:
|-
|-
|Fibrin-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|Fibrin-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|
|
|
|
|
Line 1,513: Line 1,642:
|-
|-
|Fluid overload-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|Fluid overload-associated large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|
|
|
|
|
Line 1,519: Line 1,649:
|-
|-
|Plasmablastic lymphoma||Disease||Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||GC|| ||
|Plasmablastic lymphoma||Disease||Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||GC|| ||
|
|
|
|
|
Line 1,525: Line 1,656:
|-
|-
|Primary large B-cell lymphoma of immune-privileged sites||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
|Primary large B-cell lymphoma of immune-privileged sites||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
|
|
|
|
|
Line 1,531: Line 1,663:
|-
|-
|Primary cutaneous diffuse large B-cell lymphoma, leg type||Disease|| || || || || ||GC|| ||
|Primary cutaneous diffuse large B-cell lymphoma, leg type||Disease|| || || || || ||GC|| ||
|
|
|
|
|
Line 1,537: Line 1,670:
|-
|-
|Intravascular large B-cell lymphoma||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
|Intravascular large B-cell lymphoma||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
|
|
|
|
|
Line 1,543: Line 1,677:
|-
|-
|Primary mediastinal large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|Primary mediastinal large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|
|
|
|
|
Line 1,549: Line 1,684:
|-
|-
|Mediastinal grey zone lymphoma||Disease|| || || || || ||GC|| ||
|Mediastinal grey zone lymphoma||Disease|| || || || || ||GC|| ||
|
|
|
|
|
Line 1,555: Line 1,691:
|-
|-
|High-grade B-cell lymphoma, NOS||Disease||Aiko Otsubo, PhD, Indiana University|| || || || ||GC|| ||
|High-grade B-cell lymphoma, NOS||Disease||Aiko Otsubo, PhD, Indiana University|| || || || ||GC|| ||
|
|
|
|
|
Line 1,561: Line 1,698:
|-
|-
|Burkitt lymphoma||Disease||Becky Leung, MBBS (Hons), BSc, Pathology Queensland|| || || || ||GC|| ||
|Burkitt lymphoma||Disease||Becky Leung, MBBS (Hons), BSc, Pathology Queensland|| || || || ||GC|| ||
|
|
|
|
|
Line 1,567: Line 1,705:
|-
|-
|Primary effusion lymphoma||Disease|| || || || || ||GC|| ||
|Primary effusion lymphoma||Disease|| || || || || ||GC|| ||
|
|
|
|
|
Line 1,573: Line 1,712:
|-
|-
|KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|
|
|
|
|
Line 1,579: Line 1,719:
|-
|-
|KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC|| ||
|KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC|| ||
|
|
|
|
|
Line 1,585: Line 1,726:
|-
|-
|Hyperplasias arising in immune deficiency/dysregulation||Disease|| || || || || ||GC|| ||
|Hyperplasias arising in immune deficiency/dysregulation||Disease|| || || || || ||GC|| ||
|
|
|
|
|
Line 1,591: Line 1,733:
|-
|-
|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories  Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)|| || || || ||GC|| ||
|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories  Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)|| || || || ||GC|| ||
|
|
|
|
|
Line 1,597: Line 1,740:
|-
|-
|EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC|| ||
|EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC|| ||
|
|
|
|
|
Line 1,603: Line 1,747:
|-
|-
|Lymphomas arising in immune deficiency / dysregulation||Disease|| || || || || ||GC|| ||
|Lymphomas arising in immune deficiency / dysregulation||Disease|| || || || || ||GC|| ||
|
|
|
|
|
Line 1,609: Line 1,754:
|-
|-
|Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease|| || || || || ||GC|| ||
|Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease|| || || || || ||GC|| ||
|
|
|
|
|
Line 1,615: Line 1,761:
|-
|-
|Classic Hodgkin lymphoma||Disease||Patricia V. Hernandez, M.D., Washington University School of Medicine|| || || || ||GC|| ||
|Classic Hodgkin lymphoma||Disease||Patricia V. Hernandez, M.D., Washington University School of Medicine|| || || || ||GC|| ||
|
|
|
|
|
Line 1,621: Line 1,768:
|-
|-
|Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC|| ||
|Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC|| ||
|
|
|
|
|
Line 1,634: Line 1,782:
|
|
|SG
|SG
|
|
|
|
|
Line 1,642: Line 1,791:
|-
|-
|IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
|IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
|
|
|
|
|
Line 1,648: Line 1,798:
|-
|-
|Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
|Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
|
|
|
|
|
Line 1,655: Line 1,806:
|Monoclonal gammopathy of renal significance||Disease|| || || || || ||SG
|Monoclonal gammopathy of renal significance||Disease|| || || || || ||SG
| ||
| ||
|
|
|
|
|
Line 1,662: Line 1,814:
|Immunoglobulin-related (AL) amyloidosis||Disease||Heather E. Williams, PhD, MS, PgD, ErCLG|| || || || ||SG
|Immunoglobulin-related (AL) amyloidosis||Disease||Heather E. Williams, PhD, MS, PgD, ErCLG|| || || || ||SG
| ||
| ||
|
|
|
|
|
Line 1,669: Line 1,822:
|Monoclonal immunoglobulin deposition disease||Disease||Chen Yang, MD, PhD, University of Michigan|| || || || ||SG
|Monoclonal immunoglobulin deposition disease||Disease||Chen Yang, MD, PhD, University of Michigan|| || || || ||SG
| ||
| ||
|
|
|
|
|
Line 1,676: Line 1,830:
|Mu heavy chain disease||Disease|| || || || || ||SG
|Mu heavy chain disease||Disease|| || || || || ||SG
| ||
| ||
|
|
|
|
|
Line 1,683: Line 1,838:
|Gamma heavy chain disease||Disease||Manisha Brahmbhatt-Sutariya  Asst. Professor, Dept. of Pathology and Human Anatomy  Technical Supervisor, Clinical Genetics Laboratory  Loma Linda University, Medical Center, CA|| || || || ||SG
|Gamma heavy chain disease||Disease||Manisha Brahmbhatt-Sutariya  Asst. Professor, Dept. of Pathology and Human Anatomy  Technical Supervisor, Clinical Genetics Laboratory  Loma Linda University, Medical Center, CA|| || || || ||SG
| ||
| ||
|
|
|
|
|
Line 1,690: Line 1,846:
|Alpha heavy chain disease||Disease|| || || || || ||SG
|Alpha heavy chain disease||Disease|| || || || || ||SG
| ||
| ||
|
|
|
|
|
Line 1,697: Line 1,854:
|Plasmacytoma||Disease|| || || || || ||SG
|Plasmacytoma||Disease|| || || || || ||SG
| ||
| ||
|
|
|
|
|
Line 1,704: Line 1,862:
|Plasma cell myeloma / multiple myeloma||Disease||*Huan Mo, MD, MS *Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SG
|Plasma cell myeloma / multiple myeloma||Disease||*Huan Mo, MD, MS *Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SG
| ||
| ||
|
|
|
|
|
Line 1,711: Line 1,870:
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD|| || || || ||SG
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD|| || || || ||SG
| ||
| ||
|
|
|
|
|
Line 1,721: Line 1,881:
|
|
----<br />
----<br />
|
|
|
|
|
Line 1,735: Line 1,896:
|Kikuchi-Fujimoto disease||Disease|| || || || || ||Sumi Kitahara (SK)
|Kikuchi-Fujimoto disease||Disease|| || || || || ||Sumi Kitahara (SK)
| ||
| ||
|
|
|
|
|
Line 1,741: Line 1,903:
|-
|-
|Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SK|| ||
|Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SK|| ||
|
|
|
|
|
Line 1,747: Line 1,910:
|-
|-
|Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SK|| ||
|Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SK|| ||
|
|
|
|
|
Line 1,753: Line 1,917:
|-
|-
|T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||HD|| ||
|T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||HD|| ||
|
|
|
|
|
Line 1,766: Line 1,931:
|
|
|HD
|HD
|
|
|
|
|
Line 1,781: Line 1,947:
|
|
|SK
|SK
|
|
|
|
|
Line 1,789: Line 1,956:
|-
|-
|T-large granular lymphocytic leukaemia||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
|T-large granular lymphocytic leukaemia||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
|
|
|
|
|
Line 1,795: Line 1,963:
|-
|-
|NK-large granular lymphocytic leukaemia||Disease||Michelle Don, MD|| || || || ||SK|| ||
|NK-large granular lymphocytic leukaemia||Disease||Michelle Don, MD|| || || || ||SK|| ||
|
|
|
|
|
Line 1,801: Line 1,970:
|-
|-
|Adult T-cell leukaemia/lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center|| || || || ||SK|| ||
|Adult T-cell leukaemia/lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center|| || || || ||SK|| ||
|
|
|
|
|
Line 1,807: Line 1,977:
|-
|-
|Sezary syndrome||Disease||Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina|| || || || ||SK|| ||
|Sezary syndrome||Disease||Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina|| || || || ||SK|| ||
|
|
|
|
|
Line 1,813: Line 1,984:
|-
|-
|Aggressive NK-cell leukaemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
|Aggressive NK-cell leukaemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
|
|
|
|
|
Line 1,819: Line 1,991:
|-
|-
|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
|
|
|
|
|
Line 1,825: Line 1,998:
|-
|-
|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
|
|
|
|
|
Line 1,831: Line 2,005:
|-
|-
|Mycosis fungoides||Disease||Jane Scribner, MD and Daynna J. Wolff, PhD|| || || || ||SK|| ||
|Mycosis fungoides||Disease||Jane Scribner, MD and Daynna J. Wolff, PhD|| || || || ||SK|| ||
|
|
|
|
|
Line 1,837: Line 2,012:
|-
|-
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SK|| ||
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SK|| ||
|
|
|
|
|
Line 1,843: Line 2,019:
|-
|-
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
|
|
|
|
|
Line 1,849: Line 2,026:
|-
|-
|Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SK|| ||
|Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|
|
|
Line 1,855: Line 2,033:
|-
|-
|Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SK|| ||
|Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|
|
|
Line 1,861: Line 2,040:
|-
|-
|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SK|| ||
|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|
|
|
Line 1,867: Line 2,047:
|-
|-
|Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
|Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
|
|
|
|
|
Line 1,873: Line 2,054:
|-
|-
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
|
|
|
|
|
Line 1,879: Line 2,061:
|-
|-
|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SK|| ||
|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SK|| ||
|
|
|
|
|
Line 1,885: Line 2,068:
|-
|-
|Enteropathy-associated T-cell lymphoma||Disease||*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD|| || || || ||SK|| ||
|Enteropathy-associated T-cell lymphoma||Disease||*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD|| || || || ||SK|| ||
|
|
|
|
|
Line 1,891: Line 2,075:
|-
|-
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
|
|
|
|
|
Line 1,897: Line 2,082:
|-
|-
|Intestinal T-cell lymphoma, NOS||Disease||Derick Okwan MD, PhD (Stanford Medicine, CA)  Sumire Kitahara MD (Cedars-Sinai, CA)|| || || || ||SK|| ||
|Intestinal T-cell lymphoma, NOS||Disease||Derick Okwan MD, PhD (Stanford Medicine, CA)  Sumire Kitahara MD (Cedars-Sinai, CA)|| || || || ||SK|| ||
|
|
|
|
|
Line 1,903: Line 2,089:
|-
|-
|Hepatosplenic T-cell lymphoma||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
|Hepatosplenic T-cell lymphoma||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
|
|
|
|
|
Line 1,909: Line 2,096:
|-
|-
|ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
|ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|
|
|
Line 1,915: Line 2,103:
|-
|-
|ALK-negative anaplastic large cell lymphoma||Disease||Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA|| || || || ||SK|| ||
|ALK-negative anaplastic large cell lymphoma||Disease||Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA|| || || || ||SK|| ||
|
|
|
|
|
Line 1,921: Line 2,110:
|-
|-
|Breast implant-associated anaplastic large cell lymphoma||Disease||Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center|| || || || ||SK|| ||
|Breast implant-associated anaplastic large cell lymphoma||Disease||Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center|| || || || ||SK|| ||
|
|
|
|
|
Line 1,927: Line 2,117:
|-
|-
|Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease||* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG|| || || || ||SK|| ||
|Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease||* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG|| || || || ||SK|| ||
|
|
|
|
|
Line 1,933: Line 2,124:
|-
|-
|Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SK|| ||
|Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SK|| ||
|
|
|
|
|
Line 1,939: Line 2,131:
|-
|-
|Nodal TFH cell lymphoma, NOS||Disease||Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD|| || || || ||SK|| ||
|Nodal TFH cell lymphoma, NOS||Disease||Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD|| || || || ||SK|| ||
|
|
|
|
|
Line 1,945: Line 2,138:
|-
|-
|Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
|Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
|
|
|
|
|
Line 1,951: Line 2,145:
|-
|-
|EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK|| ||
|EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|
|
|
Line 1,957: Line 2,152:
|-
|-
|Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SK|| ||
|Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|
|
|
Line 1,963: Line 2,159:
|-
|-
|Severe mosquito bite allergy||Disease|| || || || || ||SK|| ||
|Severe mosquito bite allergy||Disease|| || || || || ||SK|| ||
|
|
|
|
|
Line 1,969: Line 2,166:
|-
|-
|Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
|Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
|
|
|
|
|
Line 1,975: Line 2,173:
|-
|-
|Systemic chronic active EBV disease||Disease|| || || || || ||SK|| ||
|Systemic chronic active EBV disease||Disease|| || || || || ||SK|| ||
|
|
|
|
|
Line 1,981: Line 2,180:
|-
|-
|Systemic EBV-positive T-cell lymphoma of childhood||Disease||*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA|| || || || ||SK|| ||
|Systemic EBV-positive T-cell lymphoma of childhood||Disease||*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA|| || || || ||SK|| ||
|
|
|
|
|
Line 1,991: Line 2,191:
|
|
----<br />
----<br />
|
|
|
|
|
Line 2,011: Line 2,212:
|
|
|GC
|GC
|
|
|
|
|
Line 2,026: Line 2,228:
|
|
|GC
|GC
|
|
|
|
|
Line 2,041: Line 2,244:
|
|
|GC
|GC
|
|
|
|
|
Line 2,056: Line 2,260:
|
|
|GC
|GC
|
|
|
|
|
Line 2,071: Line 2,276:
|
|
|GC
|GC
|
|
|
|
|
Line 2,086: Line 2,292:
|
|
|GC
|GC
|
|
|
|
|
Line 2,101: Line 2,308:
|
|
|GC
|GC
|
|
|
|
|
Line 2,113: Line 2,321:
|
|
----<br />
----<br />
|
|
|
|
|
Line 2,126: Line 2,335:
|-
|-
|Fanconi anaemia||Disease|| || || || || ||NA|| ||
|Fanconi anaemia||Disease|| || || || || ||NA|| ||
|
|
|
|
|
Line 2,132: Line 2,342:
|-
|-
|Bloom syndrome||Disease|| || || || || ||NA|| ||
|Bloom syndrome||Disease|| || || || || ||NA|| ||
|
|
|
|
|
Line 2,138: Line 2,349:
|-
|-
|Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA|| ||
|Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA|| ||
|
|
|
|
|
Line 2,144: Line 2,356:
|-
|-
|RASopathies||Disease|| || || || || ||NA|| ||
|RASopathies||Disease|| || || || || ||NA|| ||
|
|
|
|
|
Retrieved from "https://test.ccga.io/index.php/HAEM5:Volunteer_Assignments_and_Opportunities"